A Search Service for Abbreviation / Long Form

■ Related PubMed/MEDLINE Info.

[Related PubMed/MEDLINE]
Total Number of Papers: 440
[Display Entries]
100 entries :
      (Publication year, Descending)
100 entries :
      (Publication year, Ascending)
all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation : CR
Long Form : controlled-release
No. Year Title Co-occurring Abbreviation
1981 Relative absorption of disopyramide as determined by liquid chromatography following acute administration of standard capsules and controlled-release tablets. ---
1982 Absorption of controlled-release iron. ---
1983 Comparative multiple dose kinetics of two formulations of indomethacin. ---
1983 Plasma concentration of disopyramide given as capsules and controlled release tablets. ---
1984 [Chronic asthma in children: comparison between a delayed-action theophylline preparation and a prompt-release aminophylline preparation]. IR
1986 Comparison of a controlled-release tablet of salbutamol given twice daily with a standard tablet given four times daily in the management of chronic obstructive lung disease. ---
1986 Comparison of controlled-release diazepam capsules and placebo in patients in general practice. ---
1987 Analysis of in vitro dissolution of whole vs. half controlled-release theophylline tablets. ---
1987 Bioavailability evaluation of a controlled-release dextromethorphan liquid. DM, DP, IR
10  1987 Comparative steady state bioavailability of conventional and controlled-release formulations of albuterol. ---
11  1987 Influence of a standard meal on the absorption of controlled-release pseudoephedrine capsules. AUC, IR, Tmax
12  1987 Long-term use of controlled-release disopyramide in patients with severe ventricular arrhythmias. ---
13  1987 Transfer from immediate-release disopyramide to controlled-release disopyramide. IR
14  1988 Absorption of naproxen controlled-release tablets in fasting and postprandial volunteers. ---
15  1988 Clinical evaluation of a new controlled-release formulation of naproxen in osteoarthritis and rheumatoid arthritis. Canadian Multicentre Study Group. ---
16  1988 Comparison between steady state pharmacokinetics and effects of two once-daily, slow-release theophylline formulations in nocturnal asthma. nBH
17  1988 Controlled-release metoprolol compared with atenolol in asthmatic patients: interaction with terbutaline. FVC
18  1988 Design of a new multiple-unit controlled-release formulation of metoprolol--metoprolol CR. ---
19  1988 Effect of controlled-release metoprolol on blood pressure and exercise heart rate in hypertension: a comparison with conventional tablets. ---
20  1988 Efficacy and tolerability of a new controlled-release formulation of metoprolol: a comparison with conventional metoprolol tablets in mild to moderate hypertension. ---
21  1988 Influence of a standard meal on the absorption of a controlled release pseudoephedrine suspension. ---
22  1988 Pharmacokinetic and pharmacodynamic properties of a new controlled-release formulation of metoprolol: a comparison with conventional tablets. AUEC
23  1988 Pharmacokinetics and pharmacodynamics of controlled-release metoprolol: a comparison with atenolol. SBP
24  1988 Pharmacokinetics of diazepam during multiple dosing of a 6-mg controlled-release capsule once daily. ---
25  1988 Relative bioavailability of a controlled-release albuterol formulation for twice-daily use. IR, PTF
26  1988 The antianginal efficacy and tolerability of controlled-release metoprolol once daily: a comparison with conventional metoprolol tablets twice daily. ---
27  1989 Gastrointestinal transit of Sinemet CR in healthy volunteers. ---
28  1990 A double-blind multicentre study comparing remoxipride, controlled release formulation, with haloperidol in schizophrenia. BPRS
29  1990 Bioavailability and cardiovascular safety of Dexatrim (phenylpropanolamine hydrochloride) from a controlled-release caplet. PPA HCl
30  1990 Clinical and pharmacological study of a novel controlled release preparation of salbutamol. ---
31  1990 Conventional vs controlled-release carbamazepine: a multicentre, double-blind, cross-over study. CBZ
32  1990 Metabolic effects of controlled-release metoprolol in hypertensive men with impaired or diabetic glucose tolerance: a comparison with atenolol. HDL, LDL
33  1990 Optimal felodipine dose when combined with metoprolol in arterial hypertension: a Swedish multicenter study within primary health care. Swedish General Practitioner Felodipine Study Group. ER
34  1990 Pharmacokinetics of an oral controlled release formulation of remoxipride: a double-blind, crossover comparison with conventional formulation in chronic schizophrenics. IR
35  1990 Subjective symptoms and pharmacokinetics/dynamics of metoprolol CR in elderly subjects--a comparison with atenolol. ---
36  1991 A comparison of the efficacy and tolerability of controlled-release carbamazepine with conventional carbamazepine. CBZ
37  1991 Long-term efficacy of diltiazem controlled release versus metoprolol in patients with stable angina pectoris. ---
38  1991 Presystemic acetylation of platelets by aspirin: reduction in rate of drug delivery to improve biochemical selectivity for thromboxane A2. TXA2
39  1991 [Delayed-release salbutamol, a new beta-mimetic with prolonged action. Results of a comparative study against theophylline L.A]. ---
40  1992 Bioavailability of a new controlled-release oral naproxen formulation given with and without food. ---
41  1992 Discrepancy between bioavailability as estimated from urinary recovery of frusemide and total diuretic effect. ---
42  1992 Nocturnal oxygen saturation and sleep quality in patients with advanced chronic obstructive pulmonary disease during treatment with moderate dose CR-theophylline. COPD, TH
43  1992 The efficacy and tolerability of controlled-release dihydrocodeine tablets and combination dextropropoxyphene/paracetamol tablets in patients with severe osteoarthritis of the hips. ---
44  1993 Immediate- versus controlled-release disopyramide: importance of saturable binding. IR
45  1993 Ketoprofen controlled release (CR) in the treatment of osteoarthrosis; a double blind, randomized multicentre study of single morning versus evening dose. Norwegian Study Group of General Practitioners. ---
46  1993 Once-daily controlled release remoxipride is equieffective with twice-daily immediate release remoxipride in the treatment of schizophrenia. CGI, IR
47  1993 Pharmacokinetic and pharmacodynamic characteristics of a controlled-release formulation of trazodone versus the conventional formulation in healthy volunteers. ---
48  1993 Plasma concentrations of S-verapamil after single doses of two different galenic formulations of racemic verapamil. ---
49  1993 Terbutaline controlled-release tablets and ipratropium aerosol in nocturnal asthma. PEFR
50  1993 Therapeutic equivalence between bambuterol, 10 mg once daily, and terbutaline controlled release, 5 mg twice daily, in mild to moderate asthma. PEF
51  1994 A comparative study of the steady-state pharmacokinetics of immediate-release and controlled-release diltiazem tablets. AUCF, IR, PTF
52  1994 Acute oral loading of carbamazepine-CR and phenytoin in a double-blind randomized study of patients at risk of seizures. CBZ, PHT
53  1994 Antihypertensive efficacy of twice daily controlled release diltiazem using 24 hour intra-arterial blood pressure monitoring. ---
54  1994 Bioavailability of total and unbound disopyramide: implications for clinical use of the immediate and controlled-release dosage forms. IR
55  1994 Clinical and polysomnographic effects of trazodone CR in chronic insomnia associated with dysthymia. CAP, HAM-D, VAS
56  1994 Clinical implications of sustained dopaminergic stimulation. ---
57  1994 Daily fluctuation of plasma levels with conventional and controlled-release carbamazepine: correlation with adverse effects. CBZ, CBZ-E, FI
58  1994 Early idiopathic parkinsonism: initiation and optimization of treatment. ---
59  1994 Effects of 100 mg of controlled-release metoprolol and 100 mg of atenolol on blood pressure, central nervous system-related symptoms, and general well being. CNS, MSE, PGWB
60  1994 Felodipine versus placebo in stable effort-induced angina pectoris in patients inadequately controlled with metoprolol--a dose-finding study. ER
61  1994 Pharmacokinetics of continuous-release carbidopa/levodopa. COMT, LAAAD
62  1994 Problems with long-term levodopa therapy for Parkinson's disease. ---
63  1994 Translating safety, efficacy and compliance into economic value for controlled release dosage forms. QOL, SR
64  1994 [Evaluation of therapeutic efficacy and pharmacokinetics of controlled release of trazodone in patients with major depressive disorder]. ---
65  1995 Antianginal effect of conventional and controlled release diltiazem in stable angina pectoris. ---
66  1995 Comparison of anticonvulsant efficacy of valproate during prolonged treatment with one and three daily doses or continuous ("controlled release") administration in a model of generalized seizures in rats. i.p, i.v, PTZ, SR, VPA
67  1995 Comparison of the efficacy, tolerability and patient acceptability of once-daily bambuterol tablets against twice-daily controlled release salbutamol in nocturnal asthma. ACROBATICS Research Group. ---
68  1995 Concentration-effect relationship of levodopa in patients with Parkinson's disease after oral administration of an immediate release and a controlled release formulation. CURS sigma, IR
69  1995 Concentration-effect relationship of levodopa in patients with Parkinson's disease. IR
70  1995 Effect of entacapone, a COMT inhibitor, on the pharmacokinetics and metabolism of levodopa after administration of controlled-release levodopa-carbidopa in volunteers. 3-OMD, AUC, COMT, DOPAC, HVA, RBCs, S-COMT, Tmax
71  1995 Efficacy of controlled-release codeine in chronic non-malignant pain: a randomized, placebo-controlled clinical trial. PDI, VAS
72  1995 Entacapone in combination with standard or controlled-release levodopa/carbidopa: a clinical and pharmacokinetic study in patients with Parkinson's disease. 3-OMD, AUC, COMT, DOPAC, HVA, STD
73  1995 Oral solid controlled release dosage forms: role of GI-mechanical destructive forces and colonic release in drug absorption under fasted and fed conditions in humans. ---
74  1995 Pharmacokinetics of verapamil and norverapamil enantiomers after administration of immediate and controlled-release formulations to humans:evidence suggesting input-rate determined stereoselectivity. IR
75  1995 Plasma concentrations of morphine, morphine-3-glucuronide, and morphine-6-glucuronide after intravenous and oral administration to healthy volunteers: relationship to nonanalgesic actions. CNS, HPLC, IR, M3G, M6G
76  1995 Randomized evaluation of controlled-release codeine and placebo in chronic cancer pain. VAS
77  1995 Steady-state pharmacokinetics of hydromorphone and hydromorphone-3-glucuronide in cancer patients after immediate and controlled-release hydromorphone. H3G, IR
78  1995 The influence of food intake on the effect of two controlled release formulations of furosemide. ---
79  1995 [Aggravation of Parkinson's disease after inadequate use of levodopa in controlled-release preparations]. ---
80  1996 Analgesic efficacy of controlled-release oxycodone in postoperative pain. IR, PID, SPID, TOTPAR
81  1996 Characterization and validation of a pharmacokinetic model for controlled-release oxycodone. IR
82  1996 Differential effects of food on the bioavailability of controlled-release oxycodone tablets and immediate-release oxycodone solution. CI, IR
83  1996 Effect of destruction force on drug release from multiple unit controlled release dosage forms in humans. ---
84  1996 Effects of atropine and loperamide on the agitating force and GI transit time in dogs in drug absorption studies. GI
85  1996 Gastrointestinal physiology-regulated dogs for bioavailability evaluation of an oral controlled-release dosage form composed of pulsatile release granules. A-granule, GI, regulated dogs
86  1996 Relationship between gelation rate of controlled-release acetaminophen tablets containing polyethylene oxide and colonic drug release in dogs. RG, SG, tmax
87  1996 Steady-state bioavailability of controlled-release oxycodone in normal subjects. IR, Tmax
88  1997 A pharmacokinetic/pharmacodynamic study of controlled-release oxycodone. ---
89  1997 Comparison of a 10-mg controlled release oxybutynin tablet with a 5-mg oxybutynin tablet in urge incontinent patients. VAS
90  1997 Controlled-release oxycodone and morphine in cancer related pain. ---
91  1997 Nonlinear mixed effects modeling of single dose and multiple dose data for an immediate release (IR) and a controlled release (CR) dosage form of alprazolam. IOV, IR, OBJ
92  1997 Transmucosal, oral controlled-release, and transdermal drug administration in human subjects: a crossover study with melatonin. MT, MT6s
93  1998 A comparative study of once-daily amlodipine versus twice-daily diltiazem controlled release (CR) in the treatment of stable angina pectoris. Amlodipine Study Group. NTG
94  1998 Blunted 5-HT1A-receptor agonist-induced corticotropin and cortisol responses after long-term ipsapirone and fluoxetine administration to healthy subjects. 5-HT1A, IR
95  1998 Comparative study to determine the optimal melatonin dosage form for the alleviation of jet lag. FR, KSS, POMS
96  1998 Comparison of controlled-release and immediate-release oxycodone tablets in patients with cancer pain. IR
97  1998 Controlled-release morphine tablets in patients with chronic cancer pain: a narrative review of controlled clinical trials. IR
98  1998 Criteria to assess in vivo performance and bioequivalence of generic controlled-release formulations of carbamazepine. AEDs, MRT, tmax
99  1998 Existing and new criteria for bioequivalence evaluation of new controlled release (CR) products of carbamazepine. CBZ, IR, MRT, PK
100  1998 Long-term administration of controlled-release oxycodone tablets for the treatment of cancer pain. IR
101  1998 Relative biologic availability and pharmacokinetics of albuterol preparations in healthy Chinese. IR
102  1998 The use of controlled-release oxycodone for the treatment of chronic cancer pain: a randomized, double-blind study. IR
103  1999 A 24-week randomized trial of controlled-release physostigmine in patients with Alzheimer's disease. ADAS-Cog, CGIC
104  1999 Can a controlled-release oral dose form of oxycodone be used as readily as an immediate-release form for the purpose of titrating to stable pain control? IR
105  1999 Controlled release of diuron from an alginate-bentonite formulation: water release kinetics and soil mobility study. ---
106  1999 Controlled-release hydrophilic tablets for individualized theophylline therapy. C-T
107  1999 Extrusion and spheronization in the development of oral controlled-release dosage forms. ---
108  1999 Postoperative analgesia with controlled-release oxycodone for outpatient anterior cruciate ligament surgery. ACL
109  1999 Steady-state kinetics and dynamics of morphine in cancer patients: is sedation related to the absorption rate of morphine? CRT, IR, PD, PK
110  1999 Studies on drug release kinetics from ibuprofen-carbomer hydrophilic matrix tablets: influence of co-excipients on release rate of the drug. IBF, MCC
111  1999 Treatment and prophylaxis of psoroptic mange (sheep scab) using an ivermectin intraruminal controlled-release bolus for sheep. ---
112  2000 A randomized controlled trial comparing the efficacy of controlled-release oxybutynin tablets (10 mg once daily) with conventional oxybutynin tablets (5 mg twice daily) in patients whose symptoms were stabilized on 5 mg twice daily of oxybutynin. ---
113  2000 Acetaminophen controlled-release sprinkles versus acetaminophen immediate-release elixir in febrile children. IR
114  2000 Clinical trials of controlled-release melatonin in children with sleep-wake cycle disorders. FR
115  2000 Controlled release of carbofuran from an alginate-bentonite formulation: water release kinetics and soil mobility. ---
116  2000 Effect in vitro acidification on plaque fluid composition with and without a NaF or a controlled-release fluoride rinse. ---
117  2000 Glutaraldehyde crosslinked sodium alginate beads containing liquid pesticide for soil application. GA, Na-Alg
118  2000 Mobility of isoproturon from an alginate-bentonite controlled release formulation in layered soil. ---
119  2000 Morphine or oxycodone in cancer pain? ---
120  2000 Osmotically controlled oral drug delivery. GI
121  2001 A novel method for measuring gel strength of controlled release hydrogel tablets using a cone/plate rheometer. HPMC
122  2001 Differential occupancy of somatodendritic and postsynaptic 5HT(1A) receptors by pindolol: a dose-occupancy study with [11C]WAY 100635 and positron emission tomography in humans. DRN, SSRIs
123  2001 Double-blind, randomized comparison of the analgesic and pharmacokinetic profiles of controlled- and immediate-release oral oxycodone in cancer pain patients. IR
124  2001 Mobility of atrazine from alginate-bentonite controlled release formulations in layered soil. CL
125  2001 Physostigmine for Alzheimer's disease. AChE, AD
126  2001 Preclinical evaluation of pharmacokinetic-pharmacodynamic rationale for oral CR metformin formulation. CR-GRDF, i.v, PD, PK
127  2001 The effect of formulation composition and dissolution parameters on the gel strength of controlled release hydrogel tablets. HPC, HPMC
128  2001 The use of oxycodone in cancer-related pain: a literature review. IR
129  2002 An adjusted pharmacokinetic equation for predicting drug levels in vivo based on in vitro square root of time release kinetics. HPMC
130  2002 Development of controlled release matrix pellets by annealing with micronized water-insoluble or enteric polymers. EC, HPMCAS, MFT, TEC
131  2002 Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study). COMT, ECG, PD, UPDRS
132  2002 Efficacy and tolerability of controlled-release and immediate-release paroxetine in the treatment of depression. IR
133  2002 Preoperative administration of controlled-release oxycodone for the management of pain after ambulatory laparoscopic tubal ligation surgery. PACU, VAS
134  2002 The effect of controlled release tablet performance and hydrogel strength on in vitro/in vivo correlation. HPC, HPMC, PE
135  2003 A double-blind, placebo-controlled study of the efficacy and safety of controlled-release fluvoxamine in patients with obsessive-compulsive disorder. CGI-I, CGI-S, OCD, Y-BOCS
136  2003 A multi-mechanistic drug release approach in a bead dosage form and in vitro/in vivo correlations. IVIVC
137  2003 A multi-mechanistic drug release approach in a bead dosage form and in vivo predictions. ---
138  2003 A multimechanistic drug release approach in a bead dosage form and in vitro predictions. ---
139  2003 Confirmation of the neurophysiologically predicted therapeutic effects of trazodone on its target symptoms depression, anxiety and insomnia by postmarketing clinical studies with a controlled-release formulation in depressed outpatients. HAMD, SARI, SAS, SDS
140  2003 Controlled-release oxycodone for pain in diabetic neuropathy: a randomized controlled trial. ---
141  2003 Controlled-release oxycodone relieves neuropathic pain: a randomized controlled trial in painful diabetic neuropathy. QOL
142  2003 Conversion to oral controlled-release oxycodone from intravenous opioid analgesic in the postoperative setting. IV-PCA
143  2003 Efficacy and tolerability of controlled-release paroxetine. SSRI
144  2003 Evaluation of dosing guidelines for use of controlled-release codeine in chronic noncancer pain. ---
145  2003 Improving antidepressant adherence. SR
146  2003 Metoprolol, a beta-1 selective blocker, can be used safely in coronary artery disease patients with chronic obstructive pulmonary disease. CAD, COPD
147  2003 Normal-release and controlled-release oxycodone: pharmacokinetics, pharmacodynamics, and controversy. ---
148  2003 Novel levodopa gastroretentive dosage form: in-vivo evaluation in dogs. GRDF
149  2003 Paroxetine controlled release in the treatment of menopausal hot flashes: a randomized controlled trial. ---
150  2003 Paroxetine treatment of mood disorders in women: premenstrual dysphoric disorder and hot flashes. PMDD, SSRI
151  2003 Pharmacodynamic equivalence of two flecainide acetate formulations in patients with paroxysmal atrial fibrillation by QRS analysis of ambulatory electrocardiogram. IR
152  2003 Pharmacokinetics and pharmacodynamics of a novel nizatidine controlled-release formulation in healthy subjects. IR
153  2003 Press-coating of immediate release powders onto coated controlled release tablets with adhesives. IR, PEG, TEC
154  2003 Randomized, double-blind, placebo-controlled comparison of the analgesic efficacy of oxycodone 10 mg/acetaminophen 325 mg versus controlled-release oxycodone 20 mg in postsurgical pain. ---
155  2004 A comparison of the direct costs and cost effectiveness of serotonin reuptake inhibitors and associated adverse drug reactions. ADRs, CLAD, MEPS, QALY, SNRIs, SRIs, SSRIs
156  2004 A double-blind placebo-controlled study of controlled release fluvoxamine for the treatment of generalized social anxiety disorder. ASEX, CGI-I, CGI-S, GSAD, LSAS, PGI, SDS
157  2004 A randomized, double-blind, parallel-group comparison of controlled- and immediate-release oxybutynin chloride in urge urinary incontinence. IR, UI
158  2004 Comparison of once-daily nifedipine controlled-release with twice-daily nifedipine retard in the treatment of essential hypertension. HF, LF
159  2004 Controlled release of tebuconazole from a polymer matrix microparticle: release kinetics and length of efficacy. PMMA, PSMA
160  2004 Controlled-release oxycodone for the management of pediatric postoperative pain. ---
161  2004 Controlled-release paroxetine in the treatment of patients with social anxiety disorder. CGI, CI, LOCF, LSAS
162  2004 Cost Effectiveness of Controlled-Release Oxybutynin Compared with Immediate-Release Oxybutynin and Tolterodine in the Treatment of Overactive Bladder in the UK, France and Austria. IR, NHS, OAB
163  2004 Effectiveness of low doses of paroxetine controlled release in the treatment of major depressive disorder. CGI, HAM-D, MDD, Q-LES-Q
164  2004 Establishing the dosage equivalency of oxymorphone extended release and oxycodone controlled release in patients with cancer pain: a randomized controlled study. ER
165  2004 Evaluating the economic consequences of early antidepressant treatment discontinuation: a comparison between controlled-release and immediate-release paroxetine. IR
166  2004 Evaluation of xanthan and highly substituted galactomannan from M. scabrella as a sustained release matrix. DS
167  2004 Fluvoxamine-controlled release formulation for the treatment of generalized social anxiety disorder. ---
168  2004 Incidence of constipation associated with long-acting opioid therapy: a comparative study. ---
169  2004 Levodopa/carbidopa/entacapone (Stalevo). IR, PD
170  2004 Paroxetine controlled release for premenstrual dysphoric disorder: a double-blind, placebo-controlled trial. PMDD
171  2004 Paroxetine controlled release. PMDD
172  2004 Pharmacokinetic evaluation of an azithromycin controlled release dosage form in healthy human volunteers: a single dose study. AZI, DI, IR
173  2004 Preliminary evaluation of a new controlled-release oxybutynin in urinary incontinence. ---
174  2004 Rapid and selective UV spectrophotometric and RP-HPLC methods for dissolution studies of oxybutynin immediate-release and controlled-release formulations. OXB
175  2004 Substance use histories in patients seeking treatment for controlled-release oxycodone dependence. ---
176  2004 Temporal administration of entacapone with slow release L-dopa: pharmacokinetic profile and clinical outcome. COMT
177  2004 The antihypertensive efficacy and safety of a chronotherapeutic formulation of propranolol in patients with hypertension. ---
178  2004 Therapy switching in patients receiving long-acting opioids. ---
179  2004 Use of activated bentonites in controlled-release formulations of atrazine. ---
180  2004 [Controlled release oxycodone--a new option in the treatment of severe and very severe pain. Review of studies on neuropathic, physical activity-related and postoperative pain]. ---
181  2005 Adherence to paroxetine CR compared with paroxetine IR in a Medicare-eligible population with anxiety disorders. IR
182  2005 Assessment of the feasibility of oral controlled release in an exploratory development setting. ---
183  2005 Comparison of darifenacin and oxybutynin in patients with overactive bladder: assessment of ambulatory urodynamics and impact on salivary flow. IR, OAB, TID
184  2005 Controlled-release nifedipine and candesartan low-dose combination therapy in patients with essential hypertension: the NICE Combi (Nifedipine and Candesartan Combination) Study. ---
185  2005 Controlled-release oxycodone-induced seizures. ---
186  2005 Differences in compliance patterns across the selective serotonin reuptake inhibitors (SSRIs). IR, OR, SSRI, SSRIs
187  2005 Differences in total medical costs across the SSRIs for the treatment of depression and anxiety. IR, SSRIs
188  2005 Effectiveness and safety of oral extended-release oxymorphone for the treatment of cancer pain: a pilot study. ER
189  2005 Efficacy and safety of controlled-release oxycodone and standard therapies for postoperative pain after knee or hip replacement. ST
190  2005 Efficacy and safety of oxymorphone extended release in chronic low back pain: results of a randomized, double-blind, placebo- and active-controlled phase III study. ER
191  2005 Luteal phase dosing with paroxetine controlled release (CR) in the treatment of premenstrual dysphoric disorder. PMDD, VAS
192  2005 Oxycodone. Pharmacological profile and clinical data in chronic pain management. IR
193  2005 Paroxetine Controlled Release for Premenstrual Dysphoric Disorder: Remission Analysis Following a Randomized, Double-Blind, Placebo-Controlled Trial. PMDD, VAS
194  2005 XEDS-mapping for explaining release patterns from single pellets. ---
195  2006 A double-blind randomized dose-response study comparing daily doses of 5, 10 and 15 mg controlled-release oxybutynin: balancing efficacy with severity of dry mouth. UI, UUI
196  2006 Cardiovascular risk factors in hypertension: rationale and design of studies to investigate the effects of controlled-release carvedilol on regression of left ventricular hypertrophy and lipid profile. FDA
197  2006 COMPARE: comparison of the effects of carvedilol CR and carvedilol IR on left ventricular ejection fraction in patients with heart failure. IR, LVEF
198  2006 Controlled release of isoproturon, imidacloprid, and cyromazine from alginate-bentonite-activated carbon formulations. ---
199  2006 Controlled-release carvedilol in the treatment of essential hypertension. ABPM, DBP, SBP
200  2006 Development of a pharmacokinetic/pharmacodynamic model for carvedilol to predict beta1-blockade in patients with congestive heart failure. IR, PD, PK
201  2006 Development of controlled release formulations of carbofuran and evaluation of their efficacy against Meloidogyne incognita. POA
202  2006 Differential effects of the antimuscarinic agents darifenacin and oxybutynin ER on memory in older subjects. ER, OD
203  2006 Effects of controlled-release on the pharmacokinetics and absorption characteristics of a compound undergoing intestinal efflux in humans. API, IR, max
204  2006 Effects of Paroxetine CR on Depressive and Anxiety Symptoms: In a Community Sample of Adult Hispanic Women with Major Depression or Generalized Anxiety Disorder. ---
205  2006 Efficacy of a once-daily formulation of carvedilol for the treatment of hypertension. ---
206  2006 High-throughput evaluation of non-swellable controlled release matrix tablets. DLT
207  2006 Improving oral medicine administration in patients with swallowing problems and feeding tubes. ICU
208  2006 Long-term treatment with darifenacin for overactive bladder: results of a 2-year, open-label extension study. AEs, OAB
209  2006 Melatonin reduces night blood pressure in patients with nocturnal hypertension. ABPM, BP
210  2006 Pharmacokinetic and pharmacodynamic comparison of controlled-release carvedilol and immediate-release carvedilol at steady state in patients with hypertension. IR, PD, PK
211  2006 Pharmacokinetic profile of controlled-release carvedilol in patients with left ventricular dysfunction associated with chronic heart failure or after myocardial infarction. IR, LVD, MI, PK
212  2006 Pharmacokinetic properties of a new controlled-release formulation of carvedilol. AUC, IR, PK
213  2006 Preclinical assessment of the feasibility of applying controlled release oral drug delivery to a lead series of atypical antipsychotics. IR
214  2006 The effect of FDA approval of a generic competitor to OxyContin (oxycodone HCl controlled-release) tablets on the abuse of oxycodone. IE, PCC
215  2006 Zolpidem extended-release. ---
216  2007 A budget-impact and cost-effectiveness model for second-line treatment of major depression. HAM-D, ICER, MADRS, MCO, MDD, SSRI, WAC
217  2007 A randomized, double-blind, 8-week crossover study of once-daily controlled-release tramadol versus immediate-release tramadol taken as needed for chronic noncancer pain. IR, ITT, PDI, VAS
218  2007 A randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of topiramate controlled release in the treatment of obese type 2 diabetic patients. ---
219  2007 Assessment of dosing frequency of sustained-release opioid preparations in patients with chronic nonmalignant pain. ---
220  2007 Budesonide in Crohn's disease: findings of a compassionate-use program. AEs, CD
221  2007 Controlled-release oxycodone admissions in public and private substance abuse treatment: associations with organizational characteristics. ---
222  2007 Effect of nifedipine on adiponectin in hypertensive patients with type 2 diabetes mellitus. MP, NO
223  2007 Effectiveness and tolerability of paroxetine controlled release (CR) in the treatment of major depressive disorder: an open-label, prospective, multi-center trial in Korea. CGI-S, HAMD-17, MDD
224  2007 Efficacy of zileuton controlled-release tablets administered twice daily in the treatment of moderate persistent asthma: a 3-month randomized controlled study. FEV1, IR
225  2007 Evaluation of the effectiveness and tolerability of controlled-release diclofenac-potassium versus immediate-release diclofenac-potassium in the treatment of knee osteoarthritis. AEs, IR, VAS, WOMAC
226  2007 In vitro and in vivo studies on HPMC-K-100 M matrices containing naproxen sodium. ---
227  2007 Influences of attitudes on family physicians' willingness to prescribe long-acting opioid analgesics for patients with chronic nonmalignant pain. CNMP
228  2007 Long-term use of controlled-release oxycodone for noncancer pain: results of a 3-year registry study. ---
229  2007 Oviposition deterrence and larvicidal activity of three formulations of piperidine repellent (AI3-37220) against field populations of Stegomyia albopicta. ---
230  2007 Population pharmacokinetics of S(-)-carvedilol in healthy volunteers after administration of the immediate-release (IR) and the new controlled-release (CR) dosage forms of the racemate. IR
231  2007 Prediction of post-operative pain by an electrical pain stimulus. PM
232  2007 Premedication with controlled-release oxycodone does not improve management of postoperative pain after day-case gynaecological laparoscopic surgery. NR, VAS
233  2007 Recently approved systemic therapies for acne vulgaris and rosacea. ER, FDA
234  2007 The safety and efficacy of zileuton controlled-release tablets as adjunctive therapy to usual care in the treatment of moderate persistent asthma: a 6-month randomized controlled study. PEF, UC, ULN
235  2008 A randomized, double-blind, crossover comparison of the efficacy and safety of oral controlled-release tramadol and placebo in patients with painful osteoarthritis. ---
236  2008 A randomized, placebo-controlled trial of controlled release melatonin treatment of delayed sleep phase syndrome and impaired sleep maintenance in children with neurodevelopmental disabilities. ---
237  2008 An integrated system for dissolution studies and magnetic resonance imaging of controlled release, polymer-based dosage forms-a tool for quantitative assessment of hydrogel formation processes. HBS, MRI
238  2008 Carvedilol versus controlled-release metoprolol for elderly veterans with heart failure. HRs, VHA
239  2008 Controlled release matrix tablets of zidovudine: effect of formulation variables on the in vitro drug release kinetics. CP, EC, HPMC
240  2008 Controlled-release fluvoxamine in obsessive-compulsive disorder and social phobia. IR, OCD, SAD
241  2008 Development of a novel osmotically driven drug delivery system for weakly basic drugs. ---
242  2008 Differences in medication adherence and healthcare resource utilization patterns: older versus newer antidepressant agents in patients with depression and/or anxiety disorders. ---
243  2008 History of depressive and anxiety disorders and paroxetine response in patients with irritable bowel syndrome: post hoc analysis from a placebo-controlled study. BAI, BDI, CGI, CPS, IBS, PSS
244  2008 Leveraging elevated temperature and particle size reduction to extract API from various tablet formulations. API, ASE, IR, MAE, TPWII
245  2008 Medicaid prior authorization and controlled-release oxycodone. PA
246  2008 N-methylation and N-formylation of a secondary amine drug (varenicline) in an osmotic tablet. NFV, NMV, PEG
247  2008 Once-daily, controlled-release tramadol and sustained-release diclofenac relieve chronic pain due to osteoarthritis: a randomized controlled trial. SR
248  2008 Oral matrix tablet formulations for concomitant controlled release of anti-tubercular drugs: design and in vitro evaluations. HPC, HPMC, SGF
249  2008 Oxycodone controlled-release as first-choice therapy for moderate-to-severe cancer pain in Italian patients: results of an open-label, multicentre, observational study. ---
250  2008 Oxymorphone and oxymorphone extended release: a pharmacotherapeutic review. ER, IR
251  2008 Pain treatment with high-dose, controlled-release oxycodone: an Italian perspective. NRS
252  2008 Paroxetine: safety and tolerability issues. MDD, PD, PTSD, SAD, SSRI
253  2008 Patient-controlled analgesia versus oral controlled-release oxycodone - are they interchangeable for acute postoperative pain after laparoscopic colorectal surgeries? PCA, VAS
254  2008 Pharmacokinetic-pharmacodynamic interaction between nebicapone, a novel catechol-o-methyltransferase inhibitor, and controlled-release levodopa/carbidopa 200 mg/50 mg : randomized, double-blind, placebo-controlled, crossover study in healthy subjects. 3-OMD, COMT, GMRs, PD, S-COMT
255  2008 Pharmacokinetics, safety, and tolerability of the new antiepileptic carisbamate in the elderly. IR
256  2008 Preformulation considerations for controlled release dosage forms. Part I. Selecting candidates. DS, IR, NCE
257  2008 Preoperative administration of controlled-release oxycodone as a transition opioid for total intravenous anaesthesia in pain control after laparoscopic cholecystectomy. NRSr and NRSi, PADSS, PCA, TCIs
258  2008 Preparation and characterisation of controlled release co-spray dried drug-polymer microparticles for inhalation 1: influence of polymer concentration on physical and in vitro characteristics. DSCG
259  2008 Preparation and characterisation of controlled release co-spray dried drug-polymer microparticles for inhalation 2: evaluation of in vitro release profiling methodologies for controlled release respiratory aerosols. ---
260  2008 Switching to evidence-based once-daily beta-blockers for improved adherence to medication across the continuum of post-myocardial infarction left ventricular dysfunction and heart failure. LVD, MI
261  2009 A randomized, placebo-controlled trial of oxycodone and of gabapentin for acute pain in herpes zoster. ---
262  2009 Additive antihypertensive and antihypertrophic effects of long-acting Ca blockers in uncontrolled hypertensive patients with angiotensin-receptor blocker based treatment. ARB
263  2009 Adherence with once daily versus twice daily carvedilol in patients with heart failure: the Compliance And Quality of Life Study Comparing Once-Daily Controlled-Release Carvedilol CR and Twice-Daily Immediate-Release Carvedilol IR in Patients with Heart Failure (CASPER) Trial. CASPER, HF, IR
264  2009 Childhood abuse and treatment response in patients with irritable bowel syndrome: a post-hoc analysis of a 12-week, randomized, double-blind, placebo-controlled trial of paroxetine controlled release. BAI, BDI, CGI, CPS, IBS, IVRS, PSS
265  2009 Controlled-release oxycodone and pregabalin in the treatment of neuropathic pain: results of a multicenter Italian study. NRS
266  2009 Design and evaluation of oral bioadhesive controlled release formulations of miglitol, intended for prolonged inhibition of intestinal alpha-glucosidases and enhancement of plasma glucagon like peptide-1 levels. GLP-1, IR
267  2009 History of depressive and/or anxiety disorders as a predictor of treatment response: a post hoc analysis of a 12-week, randomized, double-blind, placebo-controlled trial of paroxetine controlled release in patients with fibromyalgia. FIQ
268  2009 History of early abuse as a predictor of treatment response in patients with fibromyalgia: a post-hoc analysis of a 12-week, randomized, double-blind, placebo-controlled trial of paroxetine controlled release. FIQ, PSS, SDS, VAS
269  2009 Immediate- and controlled-release zolpidem ingestions reported to Texas poison centers. IR
270  2009 Lignin-based formulations to prevent pesticides pollution. ---
271  2009 Low doses of controlled-release paroxetine in the treatment of late-life depression: a randomized, placebo-controlled trial. HAM-D
272  2009 Model-based decision making in early clinical development: minimizing the impact of a blood pressure adverse event. BP, PK/PD
273  2009 Neuropsychological functioning in patients with posttraumatic stress disorder following short-term paroxetine treatment. PTSD
274  2009 The influence of renal function on clinical outcome and response to beta-blockade in systolic heart failure: insights from Metoprolol CR/XL Randomized Intervention Trial in Chronic HF (MERIT-HF). CI, eGFR, HF, HR, MDRD, MERIT-HF
275  2009 The use of gastrointestinal intubation studies for controlled release development. ---
276  2010 Artesunate-clindamycin multi-kinetics and site-specific oral delivery system for antimalaric combination products. MKS_DDS
277  2010 Clinical pharmacokinetics of oral controlled-release 5-fluorocytosine. 5-FC
278  2010 Controlled release antibiotics for dry powder lung delivery. PVA
279  2010 Controlled release formulations of metribuzin: release kinetics in water and soil. CMC, CMC-KAO
280  2010 Controlled release matrix tablets of olanzapine: influence of polymers on the in vitro release and bioavailability. ---
281  2010 Development of controlled release formulations of azadirachtin-A employing poly(ethylene glycol) based amphiphilic copolymers. PEG
282  2010 Efficacy and safety of Tapentadol extended release compared with oxycodone controlled release for the management of moderate to severe chronic pain related to osteoarthritis of the knee: a randomized, double-blind, placebo- and active-controlled phase III study. ER, LSM, TEAE
283  2010 Efficacy and safety of tapentadol extended release for the management of chronic low back pain: results of a prospective, randomized, double-blind, placebo- and active-controlled Phase III study. AEs, ER, TEAEs
284  2010 Efficacy and safety of tapentadol prolonged release for chronic osteoarthritis pain and low back pain. HCl, PR
285  2010 Glipizide controlled-release tablets, with or without acarbose, improve glycaemic variability in newly diagnosed Type 2 diabetes. CGMS, GA, HbA1c, MAGE, MBG, MODD
286  2010 Importance of blood pressure control in left ventricular mass regression. BP, LV, LVMI
287  2010 Interpenetrating polymer network blend microspheres of chitosan and hydroxyethyl cellulose for controlled release of isoniazid. CS, DSC, FTIR, HEC, IPN, SEM, TGA, XRD
288  2010 Long-term safety and tolerability of tapentadol extended release for the management of chronic low back pain or osteoarthritis pain. ER, TEAEs
289  2010 Modeling the influence of cyclodextrins on oral absorption of low-solubility drugs: I. Model development. CDs, IR
290  2010 Multicenter, double-blind, placebo-controlled crossover study to assess the acute prokinetic efficacy of nizatidine-controlled release (150 and 300 mg) in patients with gastroesophageal reflux disease. CFB, DGE, GERD
291  2010 Pharmacokinetic comparison of controlled-release and immediate-release oral formulations of simvastatin in healthy Korean subjects: a randomized, open-label, parallel-group, single- and multiple-dose study. AE, IR
292  2010 Pharmacological approach to chronic visceral pain. Focus on oxycodone controlled release: an open multicentric study. NRS
293  2010 The use of zolpidem in the treatment of progressive supranuclear palsy. GABA, PSP
294  2010 Tolerability of isradipine in early Parkinson's disease: a pilot dose escalation study. PD
295  2010 Use of oxycodone controlled-release immediately after NSAIDs: a new approach to obtain good pain control. NRS, NSAIDs
296  2011 A comparison of daily average consumption (DACON) of oxycodone and oxymorphone long-acting oral tablets. CCI, DACON, DACON, ER, GLM
297  2011 Angiotensin II receptor blocker and long-acting calcium channel blocker combination therapy decreases urinary albumin excretion while maintaining glomerular filtration rate. BP, eGFR, NICE-Combi, UAE
298  2011 Application of pharmaceutical QbD for enhancement of the solubility and dissolution of a class II BCS drug using polymeric surfactants and crystallization inhibitors: development of controlled-release tablets. FSM, HPMC, PM, QbD, SE
299  2011 Controlled release systems containing solid dispersions: strategies and mechanisms. SD
300  2011 Controlled-release oxycodone tablets after transdermal-based opioid therapy in patients with cancer and non-cancer pain. EAPC, ESMO, NRS, WHO
301  2011 Development of controlled release formulations of carbofuran and imidacloprid and their bioefficacy evaluation against aphid, Aphis gossypii and leafhopper, Amrasca biguttula biguttula Ishida on potato crop. CMC, DAG
302  2011 Development of controlled-release matrix tablet of risperidone: influence of Methocel- and Ethocel-based novel polymeric blend on in vitro drug release and bioavailability. ---
303  2011 Effect of controlled-release levodopa on the microstructure of sleep in Parkinson's disease. PD, SWS
304  2011 Efficacy and safety of aceclofenac-cr and aceclofenac in the treatment of knee osteoarthritis: a 6-week, comparative, randomized, multicentric, double-blind study. OA, SAE, WOMAC
305  2011 Epithelial profiling of antibiotic controlled release respiratory formulations. TSI
306  2011 Long-term controlled-release oxycodone and pregabalin in the treatment of non-cancer pain: an observational study. NRS
307  2011 Paroxetine controlled-release formulation in the treatment of major depressive disorder: a randomized, double-blind, placebo-controlled study in Japan and Korea. IR, MDD
308  2011 Pharmacokinetic comparison of controlled- and immediate-release formulations of dexibuprofen after single and multiple oral doses in fasting healthy male Korean volunteers. IR, SD, SD
309  2011 Physiological modeling and assessments of regional drug bioavailability of danoprevir to determine whether a controlled release formulation is feasible. IR
310  2011 Release kinetics of beta-cyfluthrin from its encapsulated formulations in water. PEG, POA
311  2011 Risk of new-onset diabetes mellitus associated with beta-blocker treatment for hypertension. BB, IR, NOD
312  2011 Targeting enteral endocrinal L-cells with dietary carbohydrates, by increasing the availability of miglitol in the intestinal lumen, leads to multi-fold enhancement of plasma glucagon-like peptide-1 levels in non-diabetic canines. GLP-1, IR
313  2011 The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson's disease. BTX-A, EBM, MDS, PD, REM, rTMS, SSRIs
314  2011 The use of oral budesonide in adolescents and adults with protein-losing enteropathy after the Fontan operation. PLE
315  2012 A rapid LC-ESI-MS/MS method for the quantitation of choline, an active metabolite of citicoline: Application to in vivo pharmacokinetic and bioequivalence study in Indian healthy male volunteers. CL, MF
316  2012 An evaluation of patient and physician satisfaction with controlled-release oxybutynin 15 mg as a one-step daily dose in elderly and non-elderly patients with overactive bladder: results of the STOP study. OAB
317  2012 Content uniformity in granules for aceclofenac controlled release (CR) tablets determined using near-infrared spectroscopy and wide area illumination (WAI) Raman spectroscopy. HPLC, NIR, PLS, WAI
318  2012 Controlled release formulation of oxycodone in patients with moderate to severe chronic osteoarthritis: a critical review of the literature. OA
319  2012 Controlled-release oxycodone for the treatment of bortezomib-induced neuropathic pain in patients with multiple myeloma. BIPN, BP, NRS
320  2012 Daily average consumption of 2 long-acting opioids: an interrupted time series analysis. DACON, ER
321  2012 Decoupling the role of image size and calorie intake on gastric retention of swelling-based gastric retentive formulations: pre-screening in the dog model. GR, IR
322  2012 Development of controlled release formulations of imidacloprid employing novel nano-ranged amphiphilic polymers. CMC, DLS, IR, TEM
323  2012 Development of orally disintegrating tablets comprising controlled-release multiparticulate beads. IR, ODT
324  2012 Economic study on the impact of side effects in patients taking oxycodone controlled-release for noncancer pain. AWP, MRU
325  2012 Imputing at-work productivity loss using results of a randomized controlled trial comparing tapentadol extended release and oxycodone controlled release for osteoarthritis pain. ER
326  2012 Metabolic effect of combined telmisartan and nifedipine CR therapy in patients with essential hypertension. BP, HOMA-IR
327  2012 MRI as a tool for evaluation of oral controlled release dosage forms. MRI
328  2012 Novel composite blend microbeads of sodium alginate coated with chitosan for controlled release of amoxicillin. FTIR, MAS, SEM, XRD
329  2012 Once daily controlled release matrix tablet of Prochlorperazine maleate: influence of Ethocel and/or Methocel on in vitro drug release and bioavailability. ---
330  2012 Optimization of LY545694 tosylate controlled release tablets through pharmacoscintigraphy. ---
331  2012 Pain relief after total hip replacement: oral CR oxycodone plus IV paracetamol versus epidural levobupivacaine and sufentanil. A randomized controlled trial. POD, THR, VAS
332  2012 Randomized, double-blind, placebo-controlled study of the abuse potential of different formulations of oral oxycodone. IR
333  2012 Release kinetics of controlled release formulations of thiamethoxam employing nano-ranged amphiphilic PEG and diacid based block polymers in soil. DLS, IR, TEM
334  2012 Residue and bio-efficacy evaluation of controlled release formulations of imidacloprid against pests in soybean (Glycine max). IARI, YMV
335  2012 Safety and tolerability of once-daily controlled-release carvedilol 10-80 mg in Japanese patients with chronic heart failure. HF, IR
336  2013 A pooled analysis of patient-specific factors and efficacy and tolerability of tapentadol extended release treatment for moderate to severe chronic pain. BMI, ER
337  2013 A Randomized Phase I Evaluation of CTP-499, a Novel Deuterium-Containing Drug Candidate for Diabetic Nephropathy. DN
338  2013 Assessment of pharmacodynamic effects following oral administration of crushed morphine sulfate and naltrexone hydrochloride extended-release capsules compared with crushed morphine sulfate controlled-release tablets and placebo in nondependent recreational opioid users. MSN, PK
339  2013 Budget impact analysis of tapentadol extended release for the treatment of moderate to severe chronic noncancer pain. ER, OISEs, PMPM
340  2013 Comparison of pharmacokinetics between sarpogrelate hydrochloride immediate-release formulation and controlled-release formulation. AUC, IR
341  2013 Composite measure to assess efficacy/gastrointestinal tolerability of tapentadol ER versus oxycodone CR for chronic pain: pooled analysis of randomized studies. ER
342  2013 Controlled-release oxycodone and naloxone in the treatment of chronic low back pain: a placebo-controlled, randomized study. ---
343  2013 Curse of the ghost pills: the role of oral controlled-release formulations in the passage of empty intact shells in faeces. Two case reports and a literature review relevant to psychiatry. ---
344  2013 Development of a HPMC-based controlled release formulation with hot melt extrusion (HME). API, DMA, DSC, HME, HPMC, PG, Tg, TGA, XRPD
345  2013 Development of controlled release formulations of thiram employing amphiphilic polymers and their bioefficacy evaluation in seed quality enhancement studies. PEG, POA
346  2013 Efficacy and safety of oral tapentadol extended release in Japanese and Korean patients with moderate to severe, chronic malignant tumor-related pain. CI, ER, TEAEs
347  2013 Efficacy of tapentadol ER for managing moderate to severe chronic pain. DPN, ER
348  2013 Feasibility of regression of hypertension using contemporary antihypertensive agents. ARB
349  2013 Luteal phase and symptom-onset dosing of SSRIs/SNRIs in the treatment of premenstrual dysphoria: clinical evidence and rationale. PMD, SNRIs, SSRIs
350  2013 Opioid rotation in patients initiated on oxycodone or morphine: a register study. ---
351  2013 Opioid utilization patterns among medicare patients with diabetic peripheral neuropathy. DPN, ER, GI, LAOs, MUE, SAOs, SR
352  2013 Phase II safety, tolerability, and dose selection study of isradipine as a potential disease-modifying intervention in early Parkinson's disease (STEADY-PD). PD, UPDRS
353  2013 Sustained safety and efficacy of once-daily hydromorphone extended-release (OROS hydromorphone ER) compared with twice-daily oxycodone controlled-release over 52 weeks in patients with moderate to severe chronic noncancer pain. ---
354  2013 Validity testing of patient objections to acceptance of tamper-resistant opioid formulations. TRFs
355  2013 [Oral therapy algorithm for the treatment of postoperative pain. A prospective observational study]. ENT, IR, NRS
356  2014 Applications of linking PBPK and PD models to predict the impact of genotypic variability, formulation differences, differences in target binding capacity and target site drug concentrations on drug responses and variability. PBPK, PDs, PKs
357  2014 Changes in prevalence of prescription opioid abuse after introduction of an abuse-deterrent opioid formulation. ADF, CI, ER, RR
358  2014 Clinical and economic evaluation of tapentadol extended release and oxycodone/naloxone extended release in comparison with controlled release oxycodone in musculoskeletal pain. CNS, ER, GE, QALY, RCTs
359  2014 Comparison of the efficacy and safety profile of morning administration of controlled-release simvastatin versus evening administration of immediate-release simvastatin in chronic kidney disease patients with dyslipidemia. CKD, IR
360  2014 Controlled release of therapeutic antibody formats. CNS
361  2014 Controlled-release oxycodone versus naproxen at home after ambulatory surgery: a randomized controlled trial. ---
362  2014 Design, in vitro release characterization and pharmacokinetics of novel controlled release pellets containing levodropropizine. IR, LDP, SR
363  2014 Development of Process Analytical Technology (PAT) methods for controlled release pellet coating. API, CQAs, NIR, PAT, QbD
364  2014 Effects of aprepitant on the pharmacokinetics of controlled-release oral oxycodone in cancer patients. ---
365  2014 Efficacy and Safety of Aceclofenac Controlled Release in Patients with Knee Osteoarthritis: A 4-week, Multicenter, Randomized, Comparative Clinical Study. IR, KOOS, OA, ROM, VAS
366  2014 Efficacy and tolerability of controlled-release oxycodone for oxaliplatin-induced peripheral neuropathy and the extension of FOLFOX therapy in advanced colorectal cancer patients. CRC, OIPN
367  2014 Evaluation of blood pressure and heart rate in patients with hypertension who received tapentadol extended release for chronic pain: a post hoc, pooled data analysis. bpm, DBP, ER, SBP, SE
368  2014 Guar gum as platform for the oral controlled release of therapeutics. GG
369  2014 Influence of formulation on mobility of metazachlor in soil. SC
370  2014 Nifedipine controlled-release 40 mg b.i.d. in Japanese patients with essential hypertension who responded insufficiently to nifedipine controlled-release 40 mg q.d.: a phase III, randomized, double-blind and parallel-group study. BP, DBP
371  2014 Once daily controlled-release pregabalin in the treatment of patients with fibromyalgia: a phase III, double-blind, randomized withdrawal, placebo-controlled study. AE, LTR
372  2014 Pharmacokinetics of pregabalin controlled-release in healthy volunteers: effect of food in five single-dose, randomized, clinical pharmacology studies. IR
373  2014 Pregabalin controlled-release pharmacokinetics in healthy volunteers: analysis of four multiple-dose randomized clinical pharmacology studies. AUC24, IR
374  2014 Safety and tolerability of tapentadol extended release in moderate to severe chronic osteoarthritis or low back pain management: pooled analysis of randomized controlled trials. AEs, ER, HCl, TEAE
375  2014 Study the effect of formulation variables on drug release from hydrophilic matrix tablets of milnacipran and prediction of in-vivo plasma profile. DE, HPMC, MDT, MRT
376  2014 Tapentadol prolonged release for managing moderate to severe, chronic malignant tumor-related pain. CI, OR, PR, TEAEs
377  2014 The controlled release of bioactive compounds from lignin and lignin-based biopolymer matrices. ---
378  2015 "Rolling" phenomenon in twin screw granulation with controlled-release excipients. ---
379  2015 A Retrospective, Pooled Suicidality Evaluation of Ropinirole Immediate Release and Controlled Release for the Treatment of Restless Legs Syndrome. IR, RLS
380  2015 Analysis of the impact of controlled release formulations on oral drug absorption, gut wall metabolism and relative bioavailability of CYP3A substrates using a physiologically-based pharmacokinetic model. AUC, IR, PBPK
381  2015 Application of physiologically based pharmacokinetic modeling in the prediction of pharmacokinetics of bicyclol controlled-release formulation in human. IR, PBPK, PK
382  2015 Controlled release of therapeutics using interpenetrating polymeric networks. IPN
383  2015 Design and in vivo evaluation of oxycodone once-a-day controlled-release tablets. HPMC
384  2015 Development and preliminary validation of an integrated efficacy-tolerability composite measure for the evaluation of analgesics. AEs, ER, ETC
385  2015 Development of controlled release nanoformulations of carbendazim employing amphiphilic polymers and their bioefficacy evaluation against Rhizoctonia solani. PEGs, POA, WP
386  2015 Effect of the gastrointestinal prokinetic agent erythromycin on the pharmacokinetics of pregabalin controlled-release in healthy individuals: a phase I, randomized crossover trial. ---
387  2015 Electrospun nanofibers as a potential controlled-release solid dispersion system for poorly water-soluble drugs. DSC, HPMC, PRX, SD, SEM, XPRD
388  2015 In Situ Perfusion Model in Rat Colon for Drug Absorption Studies: Comparison with Small Intestine and Caco-2 Cell Model. Fa
389  2015 Long-term safety and efficacy of high-dose controlled-release nifedipine (80 mg per day) in Japanese patients with essential hypertension. b.i.d, BP, CCB
390  2015 Long-term Safety and Efficacy of Tapentadol Extended Release Following up to 2 Years of Treatment in Patients With Moderate to Severe, Chronic Pain: Results of an Open-label Extension Trial. ER
391  2015 Multiple-Dose Study to Evaluate Pharmacokinetics, Pharmacodynamics, and Safety in Healthy Subjects: A Comparison of Controlled-Release Sarpogrelate and Immediate-Release Sarpogrelate. IR
392  2015 Opioid Concentrations in Oral Fluid and Plasma in Cancer Patients With Pain. OFL, TD
393  2015 Oxycodone for cancer-related pain. CENTRAL, CI, ICTRP, IR, mRCT, SMD
394  2015 Pharmacoscintigraphy studies to assess the feasibility of a controlled release formulation of ziprasidone. CCSD
395  2015 Safety and effectiveness of controlled-release paroxetine in routine clinical practice: results of a postmarketing surveillance study of patients with depression. CGI-GI, CGI-SI, CI
396  2015 Successful interventions in decreasing oxycodone CR prescriptions within an underserved population. ---
397  2015 Tolerability and efficacy of tapentadol extended release in elderly patients ≥ 75 years of age with chronic osteoarthritis knee or low back pain. ER, TEAEs
398  2016 Alternative methods for CYP2D6 phenotyping: comparison of dextromethorphan metabolic ratios from AUC, single point plasma, and urine. DM, MRDM/DX, MRs
399  2016 Controlled release drug delivery systems to improve post-operative pharmacotherapy. LAs, NSAIDs
400  2016 Cost-effectiveness analysis of oxycodone with naloxone versus oxycodone alone for the management of moderate-to-severe pain in patients with opioid-induced constipation in Canada. OIC, QALYs
401  2016 Eco-friendly PEG-based controlled release nano-formulations of Mancozeb: Synthesis and bioefficacy evaluation against phytopathogenic fungi Alternaria solani and Sclerotium rolfsii. ED50, PEGs
402  2016 Effects of Zolpidem CR on Sleep and Nocturnal Ventilation in Patients with Heart Failure. AHI
403  2016 Efficacy and safety of fulranumab as monotherapy in patients with moderate to severe, chronic knee pain of primary osteoarthritis: a randomised, placebo- and active-controlled trial. DB, FDA, NGF, OA, OAPI
404  2016 Patient-relevant outcomes and health-related quality of life in patients with chronic, severe, noncancer pain treated with tapentadol prolonged release-Using criteria of health technology assessment. HRQoL, MID, PR, RR
405  2016 The Adverse Events of Oxycodone in Cancer-Related Pain: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. AEs, CIs, Mc, RR
406  2016 The Controlled Release of Drugs and Bioactive Compounds from Mesoporous Silica Nanoparticles. MSNs
407  2016 Utility of PBPK Absorption Modeling to Guide Modified Release Formulation Development of Gaboxadol, a Highly Soluble Compound With Region-Dependent Absorption. IR, PBPK
408  2017 An innovative method for the preparation of high API-loaded hollow spherical granules for use in controlled-release formulation. API, PSD
409  2017 Assessing the impact of prescribing directives on opioid prescribing practices among Veterans Health Administration providers. FDA, VHA
410  2017 Blend Hydrogel Microspheres of Carboxymethyl Chitosan and Gelatin for the Controlled Release of 5-Fluorouracil. 5-FU, CMCS, DSC, FTIR, GA, GE, SEM, XRD
411  2017 Clinical evaluation of ropinirole controlled-release formulation at 18-24mg/day in Japanese patients with Parkinson's disease. ---
412  2017 Comparison of ambulatory blood pressure-lowering effects of higher doses of different calcium antagonists in uncontrolled hypertension: the Calcium Antagonist Controlled-Release High-Dose Therapy in Uncontrolled Refractory Hypertensive Patients (CARILLON) Study. BP, CARILLON
413  2017 Conversion to carbidopa and levodopa extended-release (IPX066) followed by its extended use in patients previously taking controlled-release carbidopa-levodopa for advanced Parkinson's disease. CD-LD, IR, PD
414  2017 Dialyzability of Oxycodone and Its Metabolites in Chronic Noncancer Pain Patients with End-Stage Renal Disease. HD, HDF
415  2017 Efficacy and Safety of Different Aceclofenac Treatments for Chronic Lower Back Pain: Prospective, Randomized, Single Center, Open-Label Clinical Trials. CLBP, EQ-5D, ODI, VAS
416  2017 Efficacy and Safety of Once-Daily Controlled-Release Pregabalin for the Treatment of Patients With Postherpetic Neuralgia: A Double-Blind, Enriched Enrollment Randomized Withdrawal, Placebo-Controlled Trial. LTR
417  2017 Interleukin-6 increases the expression of key proteins associated with steroidogenesis in human NCI-H295R adrenocortical cells. AP-1, IL-6, JAK, SE, SF-1, StAR, STAT
418  2017 Mechanistic Approach to Understanding the Influence of USP Apparatus I and II on Dissolution Kinetics of Tablets with Different Operating Release Mechanisms. IR
419  2017 Nanomedicine for prostate cancer using nanoemulsion: A review. NE, PCa
420  2017 Oxycodone for cancer-related pain. CENTRAL, CI, IR, RR, SMD
421  2017 Single- and multiple-dose pharmacokinetics and tolerability of a paroxetine controlled-release tablet in healthy Chinese subjects
. ---
422  2017 Tapentadol prolonged-release for moderate-to-severe chronic osteoarthritis knee pain: a double-blind, randomized, placebo- and oxycodone controlled release-controlled study. LS, PR
423  2018 A Double-Blind, Placebo-Controlled, Phase II Study to Determine the Efficacy, Safety, Tolerability and Pharmacokinetics of a Controlled Release (CR) Formulation of Mazindol in Adults with DSM-5 Attention-Deficit/Hyperactivity Disorder (ADHD). ADHD, CGI-I, HR, MINI
424  2018 Cebranopadol: A Novel, First-in-Class, Strong Analgesic: Results from a Randomized Phase IIa Clinical Trial in Postoperative Acute Pain. IMP, NOP, SPI, TEAE
425  2018 Comparative effectiveness of switching paroxetine formulation for treatment of major depressive disorder: an open-label multicenter study. ADRs, CGI-S, IR, MDD
426  2018 Efficacy and safety of tapentadol prolonged release formulation in the treatment of elderly patients with moderate-to-severe chronic osteoarthritis knee pain: a pooled analysis of two double-blind, randomized, placebo-, and active-controlled trials. OA, PR
427  2018 Efficacy, tolerability and acceptability of oxycodone for cancer-related pain in adults: an updated Cochrane systematic review. ---
428  2018 Evaluation of the effects of food on levodropropizine controlled-release tablet and its pharmacokinetic profile in comparison to that of immediate-release tablet. AEs, CIs, GMRs, IR, PK
429  2018 Person-level changes in oxycodone use after the introduction of a tamper-resistant formulation in Australia. CI, HR, IRR, OR
430  2018 PLGA nanoparticles are effective to control the colonic release and absorption on ibuprofen. NPs, PLGA
431  2018 Preclinical models for colonic absorption, application to controlled release formulation development. ---
432  2019 A gastrointestinal simulation system for dissolution of oral solid dosage forms before and after Roux-en-Y gastric bypass. GISS, IR, RYGB
433  2019 Bayesian knowledge integration for an in vitro-in vivo correlation model. IR, IVIVC, ODEs, PK, TD
434  2019 Development and evaluation of dexibuprofen formulation with fast onset and prolonged effect. HPMC, SLS
435  2019 Increases in controlled-release oxycodone utilisation following the subsidy of oxycodone with naloxone formulations: An Australian population-based study. RD
436  2019 Outcomes Associated with Treatment of Chronic Pain with Tapentadol Compared with Morphine and Oxycodone: A UK Primary Care Observational Study. CPRD, HES, IRRs, PR
437  2019 Physiologically based absorption modeling to predict bioequivalence of controlled release and immediate release oral products. BE, GI, IR
438  2019 Randomized, crossover questionnaire survey of acceptabilities of controlled-release mesalazine tablets and granules in ulcerative colitis patients. UC
439  2019 Will controlled release mebeverine be able to surpass placebo in treatment of diarrhoea predominant irritable bowel syndrome? IBS, IBS-D, IBS-QOL, NoBM7d, OPD
440  2020 Amphiphilic polymer based nanoformulations of mancozeb for management of early blight in tomato. ---